A postdoctoral position, with funding for about two years, is available starting by September 1, 2019 (or earlier) in the team “Genomics and epigenetics of rare tumors” led by Eric Pasmant at the Cochin Institute/INSERM in Paris, in collaboration with the team "Mechanism of repression by Polycomb proteins" led by Raphaël Margueron at the Curie Institute.
The project will aim at developing new therapeutic approaches for Neurofibromatosis type 1 (NF1). NF1 is a genetic disease caused by mutation of NF1, a gene that normally limits cell proliferation. NF1 patients initially have one the two NF1 alleles which remains normal but is prone to become fully inactivated. When this occurs, benign tumors called neurofibromas develop and cause various health complications. In some cases, neurofibromas transform into aggressive life-threatening tumors.
The proposed project aims at identifying vulnerabilities that arise as a consequence of NF1 loss and to target these weaknesses to selectively kill NF1-deficient cells. This will involve genome-wide CRISPR/Cas9 screens, candidate hit validations using cell culture, and in vitro/in vivo (mouse) pharmacological tests. The candidate will work in close collaboration with an engineer and will have accessed to all facilities of Instituts Cochin and Curie.
Candidates should hold a PhD in Biology with experience in molecular genetics, cell culture, and/or mouse models. Fluent English and teamwork skills are required. Applications (including a CV and brief statement of motivation) should be sent to Eric Pasmant (firstname.lastname@example.org) & Raphaël Margueron (email@example.com).Apprenez-en davantage
|Intitulé||Postdoctoral position in cancer genomics at the Institut Cochin, Paris, France|
|Job location||22 rue Méchain, 75014 Paris|
|Publié||juin 13, 2019|
|Date limite d'inscription||Non Spécifiée|
|Types d'emploi||Post doc  |
|Domaines de recherche :||Recherche en cancérologie,   Biologie moléculaire,   Génétique,   Biologie cellulaire  |